Glaucoma and Dry Eye Disease: Opportunity to Assess and Treat

Dry eye disease (DED) has been found to occur at a higher prevalence in individuals with glaucoma than in individuals without glaucoma. The relationship between glaucoma and DED may be, in part, a result of glaucoma therapy. Greater number of antiglaucoma medications used and greater number of antig...

Full description

Saved in:
Bibliographic Details
Published inClinical ophthalmology (Auckland, N.Z.) Vol. 17; pp. 3063 - 3076
Main Authors Nijm, Lisa M, Schweitzer, Justin, Blackmore, Jennifer Gould
Format Journal Article
LanguageEnglish
Published Dove Medical Press Limited 31.10.2023
Dove
Dove Medical Press
Subjects
antiglaucoma medication
Bimatoprost
Glaucoma
inflammation
Medical research
Medicine, Experimental
ocular surface
Patient compliance
preservatives
quality of life
Review
Tafluprost
Online AccessGet full text

Cover

More Information
Summary:Dry eye disease (DED) has been found to occur at a higher prevalence in individuals with glaucoma than in individuals without glaucoma. The relationship between glaucoma and DED may be, in part, a result of glaucoma therapy. Greater number of antiglaucoma medications used and greater number of antiglaucoma eyedrops instilled per day have been associated with ocular surface disease in patients with glaucoma. Use of antiglaucoma medication has also been associated with higher levels of ocular surface inflammatory markers and ocular surface alterations. There is evidence to suggest that antiglaucoma medications with preservatives and, to some extent, antiglaucoma medication formulations without preservatives may contribute to ocular surface signs and symptoms. Trabeculectomy for glaucoma has also been associated with ocular surface signs related to DED; however, there may be benefits of trabeculectomy and other procedures for glaucoma due to reduced use of antiglaucoma medications. Patients with glaucoma with ocular surface disease have been found to have greater ocular surface symptoms, poorer vision-related quality of life, and poorer antiglaucoma medication adherence compared with patients with glaucoma without ocular surface disease. Because of the potential negative impact of DED on patients with glaucoma, patients with glaucoma may benefit from evaluation for DED. Management of DED in patients with glaucoma may include modifications to antiglaucoma medications and use of treatments for DED. Keywords: ocular surface, quality of life, antiglaucoma medication, inflammation, preservatives
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1177-5483
1177-5467
1177-5483
DOI:10.2147/OPTH.S420932